Study of the Role of Oncostatin M in Head and Neck Squamous Cell Carcinoma

Poitiers University Hospital

Status

Not yet enrolling

Conditions

Cytokine

Head and Neck Cancer

Treatments

Other: Biopsies and Blood collection

Study type

Interventional

Funder types

Other

Identifiers

NCT06199947

ROMCOR

Details and patient eligibility

About

The ROMCOR study will be interested in the impact and the role of oncostatin M (OSM), a cytokine belonging to IL-6 superfamily, in the physiopathology of head and neck squamous cell carcinoma. The study team will study the impact of the presence of OSM and its main receptor OSM-R2 on several survival outcomes (overall survival, progression free survival) by multiple technics such as immunohistochemistry, transcriptomic in situ assays and spatial transcriptomic. Furthermore, the study team will try to show a link between serum level of several cytokines and in situ tumoral OSM.

Enrollment

119 estimated patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

over 18 years of age;
with suspected squamous cell carcinoma of the oral cavity, oropharynx or pharyngolarynx (any stage);
with healthy, untreated contralateral mucosa and no contraindications to biopsy;
with no history of any type of cancer;
with a WHO performance status index of 0 to 2 inclusive ;
able to receive treatment according to current European Society of Medical Oncology guidelines ;
without guardianship, curatorship or subordination;
benefiting from a Social Security scheme or benefiting from one through a third party;
have given informed consent to participate in the study.

Exclusion criteria

previously pre-treated in the ear, nose, throat sphere by radiotherapy or having already received anti-cancer chemotherapy;
on long-term immunosuppressive therapy, defined as taking an immunosuppresseur, identified as such in the ATC classification, for 7 days, cortico-therapy > 7.5mg/day for more than 3 months, treatment or history of anti-CD20 treatment within the year, or regular plasmatic exchange or gamma globulin infusion;
benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection;
pregnant or breast-feeding women of childbearing age (menopause must be documented and more than 2 years old) who refuse or do not have an effective method of contraception (hormonal/mechanical: oral, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy) for the duration of the study.
final diagnosis of non-squamous cell carcinoma